| E.1 Medical condition or disease under investigation |
| E.1.1 | Medical condition(s) being investigated |
| Newly Diagnosed Medulloblastoma |
|
| E.1.1.1 | Medical condition in easily understood language |
| A malignant tumor originating from brain cells during embryo phase of life and grows in the area of brain stem. |
|
| E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
| MedDRA Classification |
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 20.0 |
| E.1.2 | Level | PT |
| E.1.2 | Classification code | 10027107 |
| E.1.2 | Term | Medulloblastoma |
| E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| E.1.3 | Condition being studied is a rare disease | Yes |
| E.2 Objective of the trial |
| E.2.1 | Main objective of the trial |
| To compare progression-free survival (PFS) by central review of a personalized intensity-modulated therapy (experimental arm; sonidegib) vs. standard therapy in the SHH-activated subgroup in post-pubertal patients with newly diagnosed standard risk medulloblastoma. |
|
| E.2.2 | Secondary objectives of the trial |
In experimental versus standard arm and in the 3 clinical subgroups
separately (SHH, WNT and pooled Group 3 & Group 4) except if
otherwise stated:
• To compare PFS by central reviewer in WNT and Group 3 & 4
subgroups
• To compare PFS by local investigator
• To compare overall survival (OS)
• To evaluate safety and tolerability profile
• To evaluate short- and long-term health-related quality of life
(HRQoL) with a particular emphasis on the social functioning scale
• To evaluate issues linked to survivorship (fear of recurrence, having
problems with insurance/mortgage, work opportunities, life plans/goals
and relationships with family or friends)
• To evaluate short- and long-term neurocognitive function (NCF)
• To evaluate short- and long-term endocrine function
• To assess the incidence of second malignancies
See protocol for the following:
Exploratory objectives
Fertility sub-study objectives (in selected centres)
Translational research objectives |
|
| E.2.3 | Trial contains a sub-study | Yes |
| E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Fertility sub-study (Version 2.0, January 14, 2021)
Aims:
• To determine the uptake and utilisation of oncofertility care,
complications of fertility preservation and barriers of delivering
oncofertility care in Medulloblastoma patients.
• To define the timing and extent of reproductive complications in
Medulloblastoma patients;
• To look at the difference in reproductive complications in those
Medulloblastoma patients who had treatment with the LDE225
(sonidegib) arm of the study compared with those that had treatment on
the arms of the study without the SMO inhibitor.
• To prospectively explore the short term medical, psychological and
practical fertility concerns that Medulloblastoma cancer patients
experience.
• To determine the reproductive risk of LDE225 (sonidegib) using mouse
models. |
|
| E.3 | Principal inclusion criteria |
Step 1: Registration
• Before patient registration/randomization/enrollment, written
informed consent must be given according to ICH/GCP, and
national/local regulations. For patients under the age of legal consent,
consent has to be obtained from the parent(s) or legal representative
according to ICH/GCP, and national/local regulations.
• FFPE tumor tissue from surgical resection and whole blood for central
pathology review must be available.
Step 2: Enrollment/randomization
• Newly diagnosed, histologically proven, genetically classified,
centrally confirmed medulloblastoma
• Molecular subtype: medulloblastoma, SHH-activated and TP53-
wildtype, M0-1; medulloblastoma, WNT-activated, M0-1;
medulloblastoma, Group 3 & Group 4, M0-1
• Histologic subtype: medulloblastoma, classic (CMB);
medulloblastoma, desmoplastic/nodular (DNMB); medulloblastoma, with
extensive nodularity (MBEN); medulloblastoma, large cell/anaplastic
(LCA)
• Post-pubertal patients (<18y of age), or adults (18 y of age and
above) in SHH-activated medulloblastoma.
• Adults (≥ 18 years) in the WNT-activated, Group 3 & Group 4
medulloblastoma.
• Patients (<18 years) must have completed puberty.
• Patients (<18 years) must have a radiologically confirmed bone age
of minimum 15 years for females and 17 years for males.
Non-SHH dependent patients under the age of 18 and SHH-activated
patients under the age of 18 with M1 disease or above should be
transferred to a paediatric site for inclusion in a pediatric site for
inclusion in a pediatric trial that fits that population.
• Clinical status within 2 weeks of randomization/enrollment:
Karnofsky 50-100
• NANO-score 0 to 9 (allowing full-blown cerebellar symptoms)
• Clinically standard-risk (centrally assessed MRI review on pre- and
postoperative MRI) defined as:
- Adult patients: total or subtotal surgical resection defined as at least
80% reduction of the contrast enhancing tumour and/or less than or
equal to 1.5 cm2 (measured in axial plane) of residual tumour on early
post-operative MRI, without and with contrast.
- Post-pubertal patients: total or near total surgical resection with less
than or equal to 1.5 cm2 (measured in axial plane) of residual tumour on
early post-operative MRI, without and with contrast
- No CNS metastasis on MRI (cranial and spinal)
- Chang stage <M2
• No evidence of extra-CNS metastasis
• Full recovery from surgery or any post-surgical complication (e.g.
bleeding, infections etc.)
• Baseline MRI as the following:
o Brain MRI: pre- and post- surgery (within 72h) MRI is mandatory.
o Spine MRI: preferably pre-operative. If not available, post-operative
is acceptable.
• Normal liver, renal and haematological function within 2 weeks of
randomization/enrollment.
• WBC ≥ 3×10^9/L
• ANC ≥ 1.5×10^9/L
• Platelet count of ≥ 100×10^9/L independent of transfusion
• Hemoglobin ≥ 10 g/dl
• Total Bilirubin ≤ 1.5 × ULN
• ALT (SGPT), AST (SGOT), alkaline phosphatase (ALP) ≤ 2.5 × ULN
• Serum creatinine < 1.5 × ULN or creatinine clearance (CrCl) >60
mL/min (the estimated GFR should be in mL/min/1.73m² unit, using the
MDRD formula)
• According to CTFG recommendations related to contraception and
pregnancy testing during clinical trials, a negative serum or urine
pregnancy test within 7 days before randomization/enrollment for
women of childbearing / reproductive potential (WOCBP).
• WOCBP must use two methods of adequate birth control, including a
highly effective method and a barrier method. Birth control during the
study treatment period and for at least 20 months after the last study
treatment is mandatory for patients who receive sonidegib For all other
patients, this period is 12 months after the last study treatment. A highly
effective method of birth control is defined as those which result in low
failure rate (i.e. less than 1% per year) when used consistently and
correctly.
• Male patients even those who have had a vasectomy must always use
a condom during treatment and for 12 months after last treatment. Men
should not donate semen during treatment and for 12 months after
ending treatment (donation of semen for the semen analyses in the 1 b
fertility project is allowed)
• Female subjects who are breast feeding must discontinue nursing
prior to the first dose of study treatment and until 20 months after the
last study treatment. |
|
| E.4 | Principal exclusion criteria |
Step 2: Enrollment/randomization
• Prior treatment for medulloblastoma
• Unavailability of central review pathology results
• Post-pubertal patients with known negative prognostic markers
(MYC/MYCN amplification and/or TP53 germline alteration in the SHH
subgroup)
• Inability to start radiotherapy within 56 days after surgery.
• Significant sensorineural hearing deficit as defined by pure tone
audiometry with bone conduction or air conduction and normal
tympanogram showing impairment ≥ 20 dB at 1-3 kHz
• Any medical contraindication to radiotherapy or chemotherapy
• Hypersensitivity to contrast medium for MRI.
• Hypersensitivity towards the active substance of any of study drugs
or their excipients
• Current use of BCRP substrates such as mitoxantrone, methotrexate,
topotecan, imatinib or irinotecan or if patient is within 5 times the halflife
of these medications
• Concurrent severe or uncontrolled medical disease (e.g., active
systemic infection, diabetes, psychiatric disorder) that, in the opinion of
the investigator, would compromise the safety of the patient or
compromise the ability of the patient to complete the study.
• Prior or second invasive malignancy, except non-melanoma skin
cancer, completely resected cervical carcinoma in situ, low risk prostate
cancer (cT1-2a N0 and Gleason score ≤ 6 and PSA < 10 ng/mL), either
totally resected or irradiated with curative intent (with PSA of less than
or equal to 0.1 ng/mL) or under active surveillance as per ESMO
guidelines. Other cancers for which the subject has completed
potentially curative treatment more than 5 years prior to diagnosis of
medulloblastoma study entry are allowed.
• Known history or current evidence of active Hepatitis B (e.g., positive
HBV surface antigen) or C (e.g., HCV RNA [qualitative] is detected)
• Known or current evidence of Human Immunodeficiency Virus (HIV)
infection (positive HIV-1/2 antibodies)
• Presence of any psychological, familial, sociological, or geographical
condition potentially hampering compliance with the study protocol and
follow-up schedule; those conditions should be discussed with the
patient before registration in the trial. |
|
| E.5 End points |
| E.5.1 | Primary end point(s) |
Progression-Free Survival (PFS) according to RAPNO assessed by central
reviewer of a personalized intensity-modulated therapy (experimental
arm; sonidegib) compared to standard therapy in SHH-activated patients
in post-pubertal patients with newly diagnosed standard risk
medulloblastoma. |
|
| E.5.1.1 | Timepoint(s) of evaluation of this end point |
[ Time Frame: 91 months after the date of recruitment of the first patient ]
Compare progression-free survival (PFS) by central review of a personalized intensity-modulated therapy (experimental arm; sonidegib) vs. standard therapy in the SHH-activated subgroup in post-pubertal patients with newly diagnosed standard risk medulloblastoma
|
|
| E.5.2 | Secondary end point(s) |
In experimental versus standard arm in 3 subgroups separately (SHH,
WNT and pooled Group 3 & Group 4) except if otherwise stated:
• PFS by central reviewer in WNT and Group 3 & Group 4 subgroups
• PFS by local investigator
• OS
• Frequencies and percentages of worst adverse events (AEs) or
laboratory event; grades according to CTCAE v.5 (with neurological,
kidney, auditory, endocrine and radiotherapy associated as AE of special
interest)
• Patient reported outcomes:
- Health-related Quality of life (HRQol): EORTC QLQ-C30 and BN20, social
functioning as scale of special interest
- Survivorship outcomes (five items from EORTC QLQ-SURV111)
• Neurocognitive function (NCF): Hopkins Verbal Learning Test,
Controlled Oral Word Association Trail Making Test Part A, Trail Making
Test Part B, cerebellar cognitive affective/Schmahmann syndrome scale. |
|
| E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. (PFS) [ when 43 PFS events are observed estimated to occur 91 months after the date of recruitment of 1st patient]
2. (OS) [ when 43 PFS events are observed estimated to occur 91 m after the date of recruitment of 1st patient]
3.safety and tolerability profile: CTCAE v5 [ when 43 PFS events are observed estimated to occur 91 months after the date of recruitment of 1st patient]
4. (HRQoL) [ when 43 PFS events are observed estimated to occur 91 m after the date of recruitment of 1st patient]
The primary HRQoL endpoint that is considered relevant for this study is social functioning. The other scales from the QLQ-C30 and BN20 considered as exploratory in nature.
5.OS[when 43 PFS events are observed estimated to occur 91 M after the date of recruitment of 1st patient
|
|
| E.6 and E.7 Scope of the trial |
| E.6 | Scope of the trial |
| E.6.1 | Diagnosis | No |
| E.6.2 | Prophylaxis | No |
| E.6.3 | Therapy | Yes |
| E.6.4 | Safety | Yes |
| E.6.5 | Efficacy | Yes |
| E.6.6 | Pharmacokinetic | No |
| E.6.7 | Pharmacodynamic | No |
| E.6.8 | Bioequivalence | No |
| E.6.9 | Dose response | No |
| E.6.10 | Pharmacogenetic | No |
| E.6.11 | Pharmacogenomic | No |
| E.6.12 | Pharmacoeconomic | No |
| E.6.13 | Others | Yes |
| E.6.13.1 | Other scope of the trial description |
| Radiotherapy, QOL, radiogenomics, neurocognitive function, long term effects, impact on fertility, biobanking |
|
| E.7 | Trial type and phase |
| E.7.1 | Human pharmacology (Phase I) | No |
| E.7.1.1 | First administration to humans | No |
| E.7.1.2 | Bioequivalence study | No |
| E.7.1.3 | Other | No |
| E.7.1.3.1 | Other trial type description | |
| E.7.2 | Therapeutic exploratory (Phase II) | Yes |
| E.7.3 | Therapeutic confirmatory (Phase III) | No |
| E.7.4 | Therapeutic use (Phase IV) | No |
| E.8 Design of the trial |
| E.8.1 | Controlled | Yes |
| E.8.1.1 | Randomised | Yes |
| E.8.1.2 | Open | Yes |
| E.8.1.3 | Single blind | No |
| E.8.1.4 | Double blind | No |
| E.8.1.5 | Parallel group | Yes |
| E.8.1.6 | Cross over | No |
| E.8.1.7 | Other | No |
| E.8.2 | Comparator of controlled trial |
| E.8.2.1 | Other medicinal product(s) | Yes |
| E.8.2.2 | Placebo | No |
| E.8.2.3 | Other | No |
| E.8.2.4 | Number of treatment arms in the trial | 2 |
| E.8.3 |
The trial involves single site in the Member State concerned
| No |
| E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
| E.8.4.1 | Number of sites anticipated in Member State concerned | 18 |
| E.8.5 | The trial involves multiple Member States | Yes |
| E.8.5.1 | Number of sites anticipated in the EEA | 36 |
| E.8.6 Trial involving sites outside the EEA |
| E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
| E.8.6.2 | Trial being conducted completely outside of the EEA | No |
| E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
| Switzerland |
| Australia |
| United Kingdom |
| Austria |
| Denmark |
| France |
| Germany |
| Italy |
| Netherlands |
| Spain |
|
| E.8.7 | Trial has a data monitoring committee | Yes |
| E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study occurs when all of the following criteria have been satisfied:
• 5 months after all patients have stopped protocol treatment.
• The trial is mature for the analysis of the primary endpoint as defined in the protocol.
• The database has been fully cleaned and frozen for this analysis. |
|
| E.8.9 Initial estimate of the duration of the trial |
| E.8.9.1 | In the Member State concerned years | 7 |
| E.8.9.1 | In the Member State concerned months | 5 |
| E.8.9.1 | In the Member State concerned days | 83 |
| E.8.9.2 | In all countries concerned by the trial years | 7 |
| E.8.9.2 | In all countries concerned by the trial months | 5 |
| E.8.9.2 | In all countries concerned by the trial days | 83 |
Print
